Rochester, NY – April 12, 2016 – Bio-Optronics Inc. is proud to announce the launch of the All New Clinical Conductor CTMS product line. This overhaul for Clinical Conductor Site includes many innovative functions, while maintaining its best characteristics enabling users to tailor the software homepage to suit their specific needs and seamlessly integrate with their workflows. This new release, the first of many, is setting a new standard in the CTMS software market by truly merging powerful functionality, maximizing usability and improving efficiency significantly – a first in the CTMS industry. This new, user-centric Clinical Conductor is more intuitive and efficient than ever before. This design puts study and organization information front and center and is intended to facilitate navigation and boost efficiency. This latest release introduces MyView, a customizable homepage that lets the user simplify or expand the homepage with tailored drag and drop tiles to create unique arrangements. MyView also allows the user to pin studies to the homepage, providing quick study updates and giving the user the homepage they need to make viewing their studies more efficient. The All New Clinical Conductor CTMS is designed to work the way you work. “Interface customization is the cornerstone of this latest version, especially in regards to the MyView page,” says Kate Yawman, Product Line Manager for Clinical Conductor CTMS. “Giving our users the ability to design their homepage personalizes the application for them more than ever before.” The All New Clinical Conductor also presents Study.Set.Go! a study set up wizard designed to create a more linear, easily understood way to set up a new study. This gives current and future users the ability to maximize efficiency and create custom study setup wizards that display the necessary fields they need to get a study started, without unnecessary fields in the way. “We are excited about the launch of the All New Clinical Conductor. Visually, the software has vastly improved, as well as the standardization of the controls and the persistent navigation. These enhancements to our application, along with the addition of MyView and Study.Set.Go! place Clinical Conductor Site at the forefront of CTMS software,” says Yawman. The All New Clinical Conductor is now available to Clinical Conductor Site users. About Clinical Conductor CTMS Clinical Conductor is the industry’s first collaborative and configurable CTMS for organizations managing or executing clinical trials. Created by Bio-Optronics, an industry-leading provider of software and services to healthcare and life sciences organizations around the world, Clinical Conductor provides users with the specific features and functionality they need to effectively collaborate with or among sites and other partners, generate in-depth and valuable trial data and reports and maximize profitability. Used by organizations around the world, Clinical Conductor provides organizations with the tools they need to continue to raise the bar in clinical research. To learn more about Clinical Conductor CTMS, please visit our Clinical Conductor page.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.